Novel therapeutic strategies in the treatment of triple-negative breast cancer

Karima Oualla; Heba M. El-Zawahry; Banu Arun; James M. Reuben; Wendy A. Woodward; Heba Gamal El-Din; Bora Lim; Nawfel Mellas; Naoto T. Ueno; Tamer M. Fouad

doi:10.1177/1758834017711380

Novel therapeutic strategies in the treatment of triple-negative breast cancer

Karima Oualla, Heba M. El-Zawahry, Banu Arun, James M. Reuben, Wendy A. Woodward, Heba Gamal El-Din, Bora Lim, Nawfel Mellas, Naoto T. Ueno, Tamer M. Fouad

Research output: Contribution to journal › Review article › peer-review

62 Scopus citations

Abstract

Triple-negative breast cancer (TNBC) is a heterogeneous subtype of breast cancer that is defined by negative estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) status. Treating patients with TNBC remains clinically challenging, as patients are not candidates for endocrine or HER2-directed therapy. As a result, chemotherapy with traditional agents such as anthracyclines and taxanes remains the only available option with moderate success. Recent discoveries have revealed that TNBC is a heterogeneous disease at the clinical, histological and molecular levels. The use of biomarkers to identify distinct subsets of TNBC that derive the greatest benefit from presently approved as well as novel therapeutics has become the main focus of current research. The aim of this review is to explore the clinical and biological complexity of TNBC as well as identify novel therapeutic options that target the various molecular subsets of TNBC.

Original language	English (US)
Pages (from-to)	493-511
Number of pages	19
Journal	Therapeutic Advances in Medical Oncology
Volume	9
Issue number	7
DOIs	https://doi.org/10.1177/1758834017711380
State	Published - Jul 1 2017

Keywords

chemotherapy
clinical trials
immunotherapy
molecular subtypes
targeted therapies
triple-negative breast cancer

ASJC Scopus subject areas

Oncology

Access to Document

10.1177/1758834017711380

Cite this

@article{160fb36704244ebd8f76e8e53634576e,

title = "Novel therapeutic strategies in the treatment of triple-negative breast cancer",

abstract = "Triple-negative breast cancer (TNBC) is a heterogeneous subtype of breast cancer that is defined by negative estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) status. Treating patients with TNBC remains clinically challenging, as patients are not candidates for endocrine or HER2-directed therapy. As a result, chemotherapy with traditional agents such as anthracyclines and taxanes remains the only available option with moderate success. Recent discoveries have revealed that TNBC is a heterogeneous disease at the clinical, histological and molecular levels. The use of biomarkers to identify distinct subsets of TNBC that derive the greatest benefit from presently approved as well as novel therapeutics has become the main focus of current research. The aim of this review is to explore the clinical and biological complexity of TNBC as well as identify novel therapeutic options that target the various molecular subsets of TNBC.",

keywords = "chemotherapy, clinical trials, immunotherapy, molecular subtypes, targeted therapies, triple-negative breast cancer",

author = "Karima Oualla and El-Zawahry, {Heba M.} and Banu Arun and Reuben, {James M.} and Woodward, {Wendy A.} and {Gamal El-Din}, Heba and Bora Lim and Nawfel Mellas and Ueno, {Naoto T.} and Fouad, {Tamer M.}",

note = "Publisher Copyright: {\textcopyright} SAGE Publications Ltd unless otherwise noted. Manuscript content on this site is licensed under Creative Commons Licenses.",

year = "2017",

month = jul,

day = "1",

doi = "10.1177/1758834017711380",

language = "English (US)",

volume = "9",

pages = "493--511",

journal = "Therapeutic Advances in Medical Oncology",

issn = "1758-8340",

publisher = "SAGE Publications Inc.",

number = "7",

}

TY - JOUR

T1 - Novel therapeutic strategies in the treatment of triple-negative breast cancer

AU - Oualla, Karima

AU - El-Zawahry, Heba M.

AU - Arun, Banu

AU - Reuben, James M.

AU - Woodward, Wendy A.

AU - Gamal El-Din, Heba

AU - Lim, Bora

AU - Mellas, Nawfel

AU - Ueno, Naoto T.

AU - Fouad, Tamer M.

N1 - Publisher Copyright: © SAGE Publications Ltd unless otherwise noted. Manuscript content on this site is licensed under Creative Commons Licenses.

PY - 2017/7/1

Y1 - 2017/7/1

N2 - Triple-negative breast cancer (TNBC) is a heterogeneous subtype of breast cancer that is defined by negative estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) status. Treating patients with TNBC remains clinically challenging, as patients are not candidates for endocrine or HER2-directed therapy. As a result, chemotherapy with traditional agents such as anthracyclines and taxanes remains the only available option with moderate success. Recent discoveries have revealed that TNBC is a heterogeneous disease at the clinical, histological and molecular levels. The use of biomarkers to identify distinct subsets of TNBC that derive the greatest benefit from presently approved as well as novel therapeutics has become the main focus of current research. The aim of this review is to explore the clinical and biological complexity of TNBC as well as identify novel therapeutic options that target the various molecular subsets of TNBC.

AB - Triple-negative breast cancer (TNBC) is a heterogeneous subtype of breast cancer that is defined by negative estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) status. Treating patients with TNBC remains clinically challenging, as patients are not candidates for endocrine or HER2-directed therapy. As a result, chemotherapy with traditional agents such as anthracyclines and taxanes remains the only available option with moderate success. Recent discoveries have revealed that TNBC is a heterogeneous disease at the clinical, histological and molecular levels. The use of biomarkers to identify distinct subsets of TNBC that derive the greatest benefit from presently approved as well as novel therapeutics has become the main focus of current research. The aim of this review is to explore the clinical and biological complexity of TNBC as well as identify novel therapeutic options that target the various molecular subsets of TNBC.

KW - chemotherapy

KW - clinical trials

KW - immunotherapy

KW - molecular subtypes

KW - targeted therapies

KW - triple-negative breast cancer

UR - http://www.scopus.com/inward/record.url?scp=85022064237&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85022064237&partnerID=8YFLogxK

U2 - 10.1177/1758834017711380

DO - 10.1177/1758834017711380

M3 - Review article

C2 - 28717401

AN - SCOPUS:85022064237

SN - 1758-8340

VL - 9

SP - 493

EP - 511

JO - Therapeutic Advances in Medical Oncology

JF - Therapeutic Advances in Medical Oncology

IS - 7

ER -

Novel therapeutic strategies in the treatment of triple-negative breast cancer

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this